Head-to-head evidence
ABBV-1758 vs ALZ-101
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
ABBV-1758
Developed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2030 · NCT07599670 (registry estimate)
ALZ-101
Developed by Alzinova AB
NCT05328115 · Phase 1 · completed
Most of the trial was randomized and blinded against placebo, but the highest-dose group was given openly rather than blinded, and only 33 people took part. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reports Part A of the trial (26 randomised participants), fewer than the trial's registered enrollment of 33.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-1758's landscape · ALZ-101's landscape